Conditions: Breast Cancer
Keywords: Breast Cancer Premenopausal Bone mineral density Cancer therapy induced bone loss zoledronic acid
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 70
Healthy volunteers: no

Brief summary:
This study examines the safety and efficacy of zoledronic acid 4 mg., given every 3 months over 24 months (infusion at month 0, 3, 6, 9, 12, 15, 18 and 21) in improving bone mineral density in premenopausal women with hormone receptor negative breast cancer and adjuvant chemotherapeutic treatment

Detailed description:

Arms:
arm 1: Zoledronic acid 4mg as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions). arm 2: Placebo as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions).

Interventions: intervention 1: Zoledronic acid intervention 2: Placebo
Intervention descriptions: intervention 1: None intervention 2: Placebo

Protocol document: